Alphabet’s Isomorphic Labs reportedly raising $2B+ for its medical research AI

In 2024, DeepMind and Isomorphic Labs released a significantly improved successor to the model. AlphaFold 3 delivers a more ...
IEEE

Local–Global Structure-Aware Geometric Equivariant Graph Representation Learning for Predicting Protein–Ligand Binding Affinity

Abstract: Predicting protein-ligand binding affinities is a critical problem in drug discovery and design. A majority of existing methods fail to accurately characterize and exploit the geometrically ...
Morning Overview on MSN

IBM, Riken, and the Cleveland Clinic simulated a 12,000-atom protein by linking quantum computers with Japanese supercomputers

In late May 2026, a research team from IBM, Japan’s RIKEN institute, and the Cleveland Clinic reported that they had ...

AI could move from decoding biology to mapping civilization, turning chaotic history into patterns that may explain how societies rise and fall

AI is moving beyond biology to decode human history, searching for hidden patterns that explain how societies rise and ...
Hosted on MSN

10x Science secures $4.8M to speed drug candidate validation

10x Science, a biotech startup founded in late 2025, has raised $4.8 million in seed funding to accelerate the characterization of AI-generated drug candidates. Its platform merges deterministic ...
Drug Target Review

The scale divide: competing strategies in AI drug discovery

Two approaches to AI in preclinical drug discovery are diverging, from multi-thousand GPU systems to models with only a ...
IEEE

In Silico Identification of Potential Plastic-Active Proteins in Fungi Through a Proteome Comparison Using the Pazy Database

Abstract: The widespread use of plastics has created a global pollution problem, posing significant environmental challenges due to their resistance to degradation. Polyethylene (PE) is the most ...
The Next Web

The company that built TikTok’s algorithm is now designing drugs for diseases pharma called undruggable

ByteDance's drug unit showed an AI-designed IL-17 inhibitor at a Boston conference. The molecule targets interactions pharma called undruggable. Only trials will tell.